** Shares of telehealth firm Hims & Hers HIMS.N fall 19.22% to $41.45 premarket
** Co says may no longer be able to sell compounded versions of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy, after US FDA removes it from shortage list
** Adds the move could lead to customers cancelling their subscriptions, affecting revenue
** Shares have risen 5 fold in the last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。